Dear actionnaire
i agree with most of what you say … but point 3 depends totally on price
I can’t see the major shareholders selling control for under $1 per share (current structure) given exciting outlook … but don’t discount what a global biomedical major may actually be willing to offer for such a platform.
on the kidney drug - if the Americans are truly coming for this company, they are coming for the kidney drug, not the eye drugs.
When the USA cavalry arrives with their cheque books, a consolidated PYC will be able to very comfortably fund the kidney trials and development … and the equivalent price will be much, much higher than current. (All imho)
Dear actionnairei agree with most of what you say … but point 3...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.020(1.77%) |
Mkt cap ! $670.7M | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.18 | $1.11 | $172.3K | 151.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 592 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 4211 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |